News
Regulatory changes, approvals and studies, each linked to its source. The study and trial columns update from PubMed and ClinicalTrials.gov.
Briefs
-
FDA advisers narrowly back easing compounding limits on BPC-157 and TB-500
An outside advisory panel voted in favor of adding several injectable peptides to the list of substances pharmacies may compound. The FDA has not announced a final decision.
-
FDA removes 12 peptides, including BPC-157, from its Category 2 list, but that does not make them legal to compound
An April update to the FDA's interim 503A bulks list removed 12 peptides from the "significant safety risk" category.
-
Health Canada warns against injecting peptides bought online, naming BPC-157 and TB-500
The advisory says unauthorized products have never been reviewed for safety, quality or effectiveness.
-
FDA approves Lilly's once-daily weight-loss pill orforglipron, sold as Foundayo
The small-molecule GLP-1 pill can be taken without food or water restrictions. In its phase 3 trial the top dose averaged an 11.2% weight loss at 72 weeks.
-
FDA approves the first oral GLP-1 for chronic weight management: the Wegovy pill
Novo Nordisk's 25 mg oral semaglutide must be taken on an empty stomach. In the OASIS 4 trial it averaged -13.6% at week 64.
-
Tirzepatide outperforms semaglutide for weight loss in the first head-to-head obesity trial
Over 72 weeks, adults without diabetes lost an average of 20.2% on tirzepatide versus 13.7% on semaglutide.